• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. The use of mechanical thrombectomy in patients with STEMI and large thrombus burden: design and rationale of the NATURE trial.

The use of mechanical thrombectomy in patients with STEMI and large thrombus burden: design and rationale of the NATURE trial.

Details
Files
DOI
10.48620/96955
Publisher DOI
10.1016/j.carrev.2026.03.002
PubMed ID
41820070
Abstract
The optimal management of patients with ST-segment elevation myocardial infarction (STEMI) with large thrombus burden (LTB) undergoing primary percutaneous coronary intervention (PCI) remains unsettled. The NATURE (clinicaltrials.gov, NCT04969471) study is a prospective, multicenter, two-arm randomized clinical trial designed to assess the safety and effectiveness of the enVast stent retriever as an adjunctive reperfusion strategy in STEMI patients with LTB undergoing primary PCI. Eligible patients consenting for trial participation are randomly allocated (1:1) to enVast-assisted mechanical thrombectomy followed by conventional PCI (experimental arm) versus standard of care (control arm). Randomization is stratified by site, time from symptom onset (≤ 3 versus >3 h) and intended use of parenteral antiplatelet agents (i.e. glycoprotein IIb/IIIa inhibitors or cangrelor). Scheduled follow-up visits take place at 30 (±7) days, 150 (±60) days, and 365 (±30) days post-randomization. The primary endpoint is the infarct size assessed by the area under the curve for creatin kinase myocardial band (CK-MB) activity. Clinical events will be adjudicated by an independent Clinical Events Committee. A central core-lab will analyse 12‑lead ECG, coronary angiography examinations, cardiac magnetic resonance imaging and echocardiography examinations. A sample size of 148 (74 per arm) STEMI patients with complete primary endpoint assessment will provide a 90% power with a two-sided 5% significance level to detect a decrease in the AUC for CK-MB by 30%. The NATURE trial is the first randomized clinical trial aimed at investigating if enVast-assisted mechanical thrombectomy as adjunctive reperfusion strategy is safe and may reduce infarct size in STEMI patients with LTB undergoing primary PCI. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT04969471.
Date Issued
2026-03-04
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Subjects
Large thrombus burden
•
Mechanical thrombectomy
•
Myocardial infarction
•
Percutaneous coronary intervention
•
Stent retriever
Language(s)
en
Author(s)
Landi, Antonio
Biscaglia, Simone
Cuculi, Florim  
Erriquez, Andrea
Bossard, Matthias  
Colombo, Antonio
Mangieri, Antonio
Meuwissen, Martijn
Iglesias, Juan F
Sangiorgi, Giuseppe
Lipšic, Eric
Oreglia, Jacopo Andrea
Häner, Jonas D.  
Clinic of Cardiology  
Paradies, Valeria
Crimi, Gabriele
Milzi, Andrea
Pavon, Anna Giulia
Leo, Laura Anna
Frigoli, Enrico  
Valgimigli, Marco  
Clinic of Cardiology  
Additional Credits
Clinic of Cardiology  
Journal
Cardiovascular Revascularization Medicine
Publisher
Elsevier
ISSN
1878-0938
1553-8389
Access(Rights)
restricted
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify